JP2023538112A5 - - Google Patents

Info

Publication number
JP2023538112A5
JP2023538112A5 JP2023512371A JP2023512371A JP2023538112A5 JP 2023538112 A5 JP2023538112 A5 JP 2023538112A5 JP 2023512371 A JP2023512371 A JP 2023512371A JP 2023512371 A JP2023512371 A JP 2023512371A JP 2023538112 A5 JP2023538112 A5 JP 2023538112A5
Authority
JP
Japan
Prior art keywords
manipulated
polynucleotide
acid sequence
meganuclease
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023512371A
Other languages
English (en)
Japanese (ja)
Other versions
JP7721637B2 (ja
JP2023538112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046987 external-priority patent/WO2022040582A1/en
Publication of JP2023538112A publication Critical patent/JP2023538112A/ja
Publication of JP2023538112A5 publication Critical patent/JP2023538112A5/ja
Priority to JP2025126866A priority Critical patent/JP2025172742A/ja
Application granted granted Critical
Publication of JP7721637B2 publication Critical patent/JP7721637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023512371A 2020-08-21 2021-08-20 トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ Active JP7721637B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025126866A JP2025172742A (ja) 2020-08-21 2025-07-30 トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068965P 2020-08-21 2020-08-21
US63/068,965 2020-08-21
PCT/US2021/046987 WO2022040582A1 (en) 2020-08-21 2021-08-20 Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025126866A Division JP2025172742A (ja) 2020-08-21 2025-07-30 トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2023538112A JP2023538112A (ja) 2023-09-06
JP2023538112A5 true JP2023538112A5 (https=) 2024-08-01
JP7721637B2 JP7721637B2 (ja) 2025-08-12

Family

ID=77726580

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023512371A Active JP7721637B2 (ja) 2020-08-21 2021-08-20 トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ
JP2025126866A Pending JP2025172742A (ja) 2020-08-21 2025-07-30 トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025126866A Pending JP2025172742A (ja) 2020-08-21 2025-07-30 トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ

Country Status (6)

Country Link
US (1) US20240011003A1 (https=)
EP (1) EP4200412B1 (https=)
JP (2) JP7721637B2 (https=)
AU (1) AU2021329403A1 (https=)
CA (1) CA3172292A1 (https=)
WO (1) WO2022040582A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250064986A1 (en) 2022-01-07 2025-02-27 Precision Biosciences, Inc. Optimized polynucleotides for protein expression
CN116083485B (zh) * 2022-12-01 2024-09-13 四川大学华西医院 一种靶向载体、ATTRm疾病模型的构建方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP3202899B1 (en) * 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
WO2009001159A1 (en) 2007-06-25 2008-12-31 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PL2563920T3 (pl) 2010-04-29 2017-08-31 Ionis Pharmaceuticals, Inc. Modulacja ekspresji transtyretyny
EP2714936B1 (en) 2011-06-01 2018-12-12 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
CA3009637A1 (en) * 2015-12-23 2017-06-29 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
WO2019089913A1 (en) * 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
WO2019185920A1 (en) * 2018-03-29 2019-10-03 Cellectis Tale-nucleases for allele-specific codon modification

Similar Documents

Publication Publication Date Title
JP7793525B2 (ja) コロナウイルスワクチン
AU2025200483A1 (en) Coronavirus vaccine
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
WO2020002525A1 (en) Novel lassa virus rna molecules and compositions for vaccination
JP2008545406A5 (https=)
WO2017192750A1 (en) Recombinant adeno-associated viral vectors
JP2023538112A5 (https=)
JP2024180560A5 (https=)
JP2016513115A5 (https=)
Rahman et al. An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
US20250223592A1 (en) Compositions and methods for circular rna affinity purification
WO2023035372A1 (zh) 一种有限自我复制mRNA分子系统、制备方法及应用
JP2024511206A (ja) 免疫原性組成物
WO2023227124A1 (zh) 一种构建mRNA体外转录模板的骨架
JP2026063215A5 (https=)
JP2023521662A5 (https=)
Wei et al. Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Huang et al. Circular mrna vaccine against sars-cov-2 variants enabled by degradable lipid nanoparticles
CN100471957C (zh) 用于免疫治疗的腺病毒载体
JP2025170345A5 (https=)
CN101155826B (zh) 作为疫苗的复制缺陷型rna病毒
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
Xu et al. From sequence to system: Enhancing IVT mRNA vaccine effectiveness through cutting-edge technologies
US20160120974A1 (en) Semi-live respiratory syncytial virus vaccine